15:21 , Jul 19, 2018 |  BC Innovations  |  Translation in Brief

Inflammatory images

A University of Calgary team has implicated the inflammasome in acute kidney injury induced by contrast imaging agents and identified targets that could help prevent it. In patients with diminished renal function, such as those...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
03:56 , May 12, 2017 |  BC Week In Review  |  Clinical News

Atlantic begins rolling NDA submission for pouchitis candidate alicaforsen

Atlantic Healthcare plc (Saffron Walden, U.K.) began submission of a rolling NDA to FDA for alicaforsen (AP 1007) to treat pouchitis. The antisense inhibitor of intercellular adhesion molecule-1 ( ICAM-1 ; CD54) is in a...
03:55 , May 12, 2017 |  BC Week In Review  |  Clinical News

Atlantic begins rolling NDA submission for pouchitis candidate alicaforsen

Atlantic Healthcare plc (Saffron Walden, U.K.) began submission of a rolling NDA to FDA for alicaforsen (AP 1007) to treat pouchitis. The antisense inhibitor of intercellular adhesion molecule-1 ( ICAM-1 ; CD54) is in a...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
01:11 , Mar 22, 2016 |  BC Extra  |  Financial News

Atlantic raises $24M venture round

Atlantic Healthcare plc (Cambridge, U.K.) raised $24 million in a venture round from Lorin Johnson and other founders of Salix Pharmaceuticals Inc., Fullbrook Thorpe Investments, LDC and undisclosed existing investors. In 2H17, Atlantic expects results...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Clinical News

Alicaforsen: Phase III started

Atlantic began a double-blind, placebo-controlled, international Phase III trial to evaluate 240 mg topical alicaforsen enema once daily for 6 weeks in 138 patients with active, chronic, antibiotic-refractory pouchitis. Atlantic Healthcare has exclusive, worldwide rights...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Isis Pharmaceuticals other research news

ISIP researchers reported in the Journal of Biological Chemistry that addition of methoxyethyl to the 2' hydroxyl groups of an antisense oligonucleotide targeting ICAM-1 (cell adhesion molecule) efficiently inhibited ICAM-1 protein production. Treatment of human...
07:00 , May 31, 2010 |  BC Week In Review  |  Clinical News

Alicaforsen regulatory update

Atlantic Healthcare said it plans to supply alicaforsen on a named patient basis in selected EU countries to treat inflammatory bowel disease, including pouchitis. The company expects to launch the program in the fall. The...